Turn Therapeutics Inc. develops targeted therapies for dermatologic conditions, advanced wound care, and infectious diseases. The company's core technology, PermaFusion, is a patented mixing process that enables the stable suspension of active pharmaceutical ingredients without emulsifiers, designed to enhance bioavailability and reduce systemic exposure. Its lead clinical asset, GX-03, is a non-biologic topical immunomodulator being evaluated for moderate-to-severe atopic dermatitis (eczema) and onychomycosis. Additionally, Turn Therapeutics has secured FDA clearances for its Hexagen wound care products and is advancing a thermostable intranasal vaccine program. The company operates primarily in the United States and partners with larger healthcare distributors, such as Medline, for commercialization.
